Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selected to manufacture adeno-associated vectors (AAV) therapies using its suspension AAV Curator™ Platform under the California Institute for Regenerative Medicine (CIRM) Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC).
The CIRM partnership with Andelyn was established to advance BGTC’s mission to develop platforms and standards to propel the development and delivery of customized or ‘bespoke’ gene therapies for millions of people affected with rare diseases. BGTC is focusing on development of cures for eight such diseases, with Andelyn selected to optimize and scale the AAV therapy processes for the treatment of Congenital Hereditary Endothelial Dystrophy – Type 1.
Matt Niloff, Chief Commercial Officer of Andelyn, said: “As a long-standing pioneer in AAV gene therapies and historical connection to the clinic, we have great synergies with the CIRM/BGTC. Andelyn is privileged to work with the CIRM/BGTC on its first AMP established specifically for rare disease and leverage our AAV Curator™ Platform to help overcome the major obstacles related to developing gene therapies.”
Also Read: Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395
Dr. Abla Creasey, PhD, Vice President of Therapeutics Development at CIRM said: “This partnership with Andelyn will enable progress in the field and help overcome manufacturing obstacles that can potentially lead to breakthroughs for rare diseases like Congenital Hereditary Endothelial Dystrophy.”
SOURCE: PRNewswire